PF-06260414
An experimental SARM for muscle failure research has entered Phase I clinical trials.
Overview
PF-06260414 is an oral nonsteroidal SARM with potent anabolic effects in muscle, targeting sarcopenia and muscle decline in early clinical trials. It enhances muscle mass, strength, and bone health with tissue-specific benefits and fewer side effects than steroids. Used in sports nutrition research and age-related muscle wasting studies.
Synonyms: PF6260414; PF-6260414; 1-Isoquinolinecarbonitrile,6-[(4R)-tetrahydro-4-methyl-1,1-dioxido-2H-1,2,6-thiadiazin-2-yl]-; PF-06260414>=98%(HPLC); 6-((4R)-4-Methyl-1,1-dioxo-1,2,6-thiadiazinan-2-yl)isoquinoline-1-carbonitrile
Product Categories: SARM series
Mol File: 1612755-71-1.mol
Physicochemical Properties
Boiling point: 539.7±53.0°C(Predicted)
Density: 1.45±0.1g/cm3(Predicted)
Storage temp.: room temp
Solubility: DMSO: 5mg/mL, clear (warmed)
Form: powder
Color: light orange to dark orange
MSDS Information
Experimental Data
Pharmacodynamics
Mechanism Of Action
Similar Products
GSK-2881078
Therapy
: Musculoskeletal diseases
Target
: AR
CAS
: 1539314-06-1
MF
: C14H13F3N2O2S
MW
: 330.33
MK-0773
Therapy
: Musculoskeletal diseases
Target
: AR
CAS
: 606101-58-0
MF
: C27H34FN5O2
MW
: 479.59
MK-4541
Therapy
: Musculoskeletal diseases
Target
:
CAS
: 796885-38-6
MF
: C22H31F3N2O3
MW
: 428.49
LGD-2226
Therapy
: Musculoskeletal diseases
Target
:
CAS
: 328947-93-9
MF
: C14H9F9N2O
MW
: 392.22